OBJECTIVE: To evaluate the use of a mechanical stretching device, the Therabite, for the early postoperative management of trismus in select patients. DESIGN: Prospective series of consecutive head and neck cancer patients. SETTING: Academic, tertiary referral center. PARTICIPANTS: Seven patients with oropharyngeal carcinoma who underwent resection and radial forearm flap reconstruction. Five had midline mandibulotomy procedures for exposure. Six had radiation therapy (2 pre, 4 post). INTERVENTIONS: Patients were given a Therabite mechanical jaw mobilization device, were instructed in its proper use, and began using it within 6 weeks postoperatively. MAIN OUTCOME MEASURES: Maximal interincisor opening (MIO) was measured at the beginning of use and at the most recent postoperative visit. A 5-question self-assessment telephone survey was administered on study completion. RESULTS: The average MIO was 30 mm (range, 21-38 mm) at the beginning of the study and 40 mm (range, 30-57 mm) at the last visit. Average gain in MIO was 10 mm (range, 1-21 mm). Four of 5 assessable patients had minimal or no limitation on overall quality of life relative to jaw opening. No complications were associated with use of the device. Two patients could not be located for follow-up. CONCLUSIONS: The Therabite mechanical stretching device is effective and safe for the management of trismus in a select group of head and neck cancer patients after extensive ablation and complex reconstruction. Specifically, there were no adverse effects in the 5 patients who had undergone midline mandibulotomy.
OBJECTIVE: To evaluate the use of a mechanical stretching device, the Therabite, for the early postoperative management of trismus in select patients. DESIGN: Prospective series of consecutive head and neck cancerpatients. SETTING: Academic, tertiary referral center. PARTICIPANTS: Seven patients with oropharyngeal carcinoma who underwent resection and radial forearm flap reconstruction. Five had midline mandibulotomy procedures for exposure. Six had radiation therapy (2 pre, 4 post). INTERVENTIONS:Patients were given a Therabite mechanical jaw mobilization device, were instructed in its proper use, and began using it within 6 weeks postoperatively. MAIN OUTCOME MEASURES: Maximal interincisor opening (MIO) was measured at the beginning of use and at the most recent postoperative visit. A 5-question self-assessment telephone survey was administered on study completion. RESULTS: The average MIO was 30 mm (range, 21-38 mm) at the beginning of the study and 40 mm (range, 30-57 mm) at the last visit. Average gain in MIO was 10 mm (range, 1-21 mm). Four of 5 assessable patients had minimal or no limitation on overall quality of life relative to jaw opening. No complications were associated with use of the device. Two patients could not be located for follow-up. CONCLUSIONS: The Therabite mechanical stretching device is effective and safe for the management of trismus in a select group of head and neck cancerpatients after extensive ablation and complex reconstruction. Specifically, there were no adverse effects in the 5 patients who had undergone midline mandibulotomy.
Authors: Valesca P Retèl; Lisette van der Molen; Lotte M G Steuten; Michiel W van den Brekel; Frans J M Hilgers Journal: Eur Arch Otorhinolaryngol Date: 2015-02-11 Impact factor: 2.503
Authors: Adepitan A Owosho; Luciana M Pedreira Ramalho; Haley I Rosenberg; SaeHee K Yom; Esther Drill; Elyn Riedel; C Jillian Tsai; Nancy Y Lee; Joseph M Huryn; Cherry L Estilo Journal: J Craniomaxillofac Surg Date: 2016-06-16 Impact factor: 2.078
Authors: Jolanda I Kamstra; Jan L N Roodenburg; Carien H G Beurskens; Harry Reintsema; Pieter U Dijkstra Journal: Support Care Cancer Date: 2012-10-04 Impact factor: 3.603
Authors: Rana Lee; Alex Molassiotis; Simon N Rogers; Rhiannon Tudor Edwards; David Ryder; Nick Slevin Journal: BMJ Open Date: 2018-03-30 Impact factor: 2.692